Amneal Pharmaceuticals’ stock soars 14% premarket after company offers upbeat Q1 guidance

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Amneal Pharmaceuticals Inc.’s stock soared 14% in premarket trade Monday, after the generics and specialty pharmaceuticals company offered first-quarter...

Amneal Pharmaceuticals Inc.’s stock AMRX soared 14% in premarket trade Monday, after the generics and specialty pharmaceuticals company offered first-quarter guidance that topped consensus estimates. Bridgewater, N.J.-based Amneal said it expects revenue for the quarter to range from $550 million to $560 million, up about 12% from the year-earlier quarter and above the $529 million FactSet consensus.

Bridgewater, N.J.-based Amneal said it expects revenue for the quarter to range from $550 million to $560 million, up about 12% from the year-earlier quarter and above the $529 million FactSet consensus. The company is expecting its pretax loss to range from $10 million to breakeven, an improvement of about 50% from a year ago. The company’s long-term debt is expected to stand at $2.692 billion at quarter-end, while cash is expected to stand at $151 million, resulting in net debt of $2.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 3. in BR

Brasil Últimas Notícias, Brasil Manchetes